Chemical compounds

Patent metadata

Field	Value
Publication number	US-10793559-B2
Application number	US-201916572917-A
Country	US
Kind code	B2
Filing date	Sep 17, 2019
Priority date	Feb 12, 2016
Publication date	Oct 6, 2020
Grant date	Oct 6, 2020

Abstract

The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I):

and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.

First claim

What is claimed is:

1. A method of treating a disorder mediated by inappropriate PI3-kinase activity comprising administering an amount of a compound of formula (I):

wherein
R 1 is C 1-6 alkoxy or —N(C 1-6 alkyl) 2 ,
R 2 is hydrogen or C 1-6 alkyl optionally substituted by —C(O)OC 1-6 alkyl or —OC(O)C 1-6 alkyl,
R 3 , R 4 , R 5 and R 6 are each independently selected from hydrogen and halogen;
R 7 and R 8 are each independently C 1-6 alkyl, or
R 7 and R 8 , together with the nitrogen atom to which they are attached, are linked to form a 5- or 6-membered heterocyclyl wherein the 5- or 6-membered heterocyclyl optionally contains a further nitrogen atom and is optionally substituted by C 3-6 cycloalkyl, 4- to 6-membered heterocyclyl containing one or two heteroatoms independently selected from oxygen and nitrogen, or C 1-6 alkyl wherein the C 1-6 alkyl is optionally substituted by hydroxy or C 1-6 alkoxy, or
R 7 and R 8 , together with the nitrogen atom to which they are attached, are linked to form a 5- or 6-membered heterocyclyl wherein the 5- or 6-membered heterocyclyl contains an oxygen atom and is optionally substituted by one or two substituents independently selected from C 1-6 alkyl;
or a pharmaceutically acceptable salt thereof, to a patient in need thereof, by inhibiting PI3-kinase activity and wherein said disorder mediated by inappropriate PI3-kinase activity is selected from the group consisting of asthma and COPD.

2. A method according to claim 1 wherein the disorder mediated by inappropriate PI3-kinase activity is asthma.

3. A method according to claim 1 wherein the disorder mediated by inappropriate PI3-kinase activity is COPD.

Assignees

• Glaxosmithkline Ip Dev Ltd

Inventors

• Anderson Niall Andrew
• Barton Nicholas Paul
• Campos Sebastien Andre
• Cannons Edward Paul
• Cooper Anthony William James
• Down Kenneth David
• Doyle Kevin James
• Hamblin Julie Nicole
• Inglis Graham George Adam
• Le Gall Armelle
• Patel Vipulkumar Kantibhai
• Peace Simon
• Sharpe Andrew
• White Gemma Victoria

Classifications

• C07D213/76 Primary

  to which a second hetero atom is attached (nitro radicals C07D213/61) · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• C07D413/14 Primary

  containing three or more hetero rings · CPC title

• A61P25/24

  Antidepressants · CPC title